Key result
Circumferential pulmonary vein isolation using a novel endoscopic ablation system was feasible, achieving isolation in 98% of pulmonary veins, with 80% of patients free of atrial fibrillation at 168 days.
Why the study?
Is circumferential pulmonary vein isolation using a novel endoscopic ablation system feasible and safe in patients with drug refractory paroxysmal atrial fibrillation?
Observational (n=30)
Is circumferential pulmonary vein isolation using a novel endoscopic ablation system feasible and safe in patients with drug refractory paroxysmal atrial fibrillation?
The novel endoscopic ablation system is highly effective for achieving pulmonary vein isolation in paroxysmal atrial fibrillation, but carries a risk of thermal esophageal injury that warrants temperature monitoring.
No takes yet. Share an insight, caveat, or question.
Novel endoscopic laser PVI feasible and safe in small cohort; leaves open efficacy, durability, and need for randomized comparison.
Schmidt et al. (2010) conducted an observational in Drug refractory paroxysmal atrial fibrillation (n=30). Circumferential pulmonary vein isolation using a novel endoscopic ablation system was evaluated on Pulmonary vein isolation (PVI) achievement. Circumferential pulmonary vein isolation using a novel endoscopic ablation system was feasible, achieving isolation in 98% of pulmonary veins, with 80% of patients free of atrial fibrillation at 168 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: